Loading stock data…
Emergent BioSolutions Inc. (EBS)
$8.46-0.07 (-0.82%)
Market ClosedLast close Jun 29
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Emergent BioSolutions Inc. in the Healthcare sector is trading at $8.46 with a market capitalization of $409M. Wall Street consensus targets $12.00 (2 analysts), implying a +41.8% move over the next 12 months. The stock is currently 40% below its 52-week high of $14.06, remaining 13.0% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +41.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $149.70M↑ | $143.80M↓ | $222.00M↑ | $130.30M↓ | $209.10M |
| Gross Profit | $77.70M↑ | $58.90M↓ | $136.10M↑ | $63.40M↓ | $120.60M |
| Operating Income | $10.50M↑ | -$15.70M↓ | $76.50M↑ | $1.60M↓ | $49.90M |
| Net Income | $6.80M↑ | -$54.60M↓ | $51.20M↑ | -$12.00M↓ | $68.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commerc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$409.16M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.64%
Volume
Today's trading volume
554,962
Recent News
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Emergent BioSolutions Inc. (NYSE:EBS) is one of the best pharmaceutical stocks to invest in. TheFly reported on April 30 that EBS announced that Singapore’s Health Sciences Authority approved an expanded use of ACAM2000, allowing its use in preventing mpox […]
Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved
Emergent Biosolutions (NYSE:EBS) on Tuesday held its 2026 Annual Meeting of Stockholders, where shareholders voted on director elections, auditor ratification, executive compensation, and an amendment to increase shares available under the company’s stock incentive plan. Management also reviewed pro
Emergent BioSolutions Inc. Q1 2026 Earnings Call Summary
Moby summary of Emergent BioSolutions Inc.'s Q1 2026 earnings call
Emergent Biosolutions Q1 Earnings Call Highlights
Emergent Biosolutions (NYSE:EBS) reported first-quarter 2026 results that management said exceeded the high end of the company’s revenue guidance range, while continuing to emphasize progress on a multi-year transformation plan and balance sheet actions completed in April. First-quarter results top
Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights: Strong Revenue and Strategic ...
Emergent BioSolutions Inc (EBS) surpasses revenue expectations and strengthens financial position, while navigating pricing pressures and geopolitical risks.